C.R. Bard Inc. to Pay U.S. $48.26 Million to Resolve False Claims Act Claims
C.R. Bard Inc. has agreed to pay the United States $48.26 million to resolve claims that it knowingly caused false claims to be submitted to the Medicare program for brachytherapy seeds used to treat prostate cancer in violation of the False Claims Act. Bard is a New Jersey based corporation that develops, manufacturers, and markets medical products used for a variety of conditions, including prostate cancer.
Action Details
- Date:May 13, 2013
- Agency:U.S. Department of Justice
-
Enforcement Types:
- Criminal and Civil Actions